![Landos Biopharma, Inc. logo](/logos/LABP.webp)
Landos Biopharma, Inc.
NASDAQ:LABP
Overview | Financials
Company Name | Landos Biopharma, Inc. |
Symbol | LABP |
Currency | USD |
Price | 22.93 |
Market Cap | 71,675,511 |
Dividend Yield | 0% |
52-week-range | 3.145 - 22.94 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Mr. Gregory Oakes |
Website | https://landosbiopharma.com |
An error occurred while fetching data.
About Landos Biopharma, Inc.
Landos Biopharma, Inc., a clinical-stage biopharmaceutical company, discovers and develops oral therapeutics for patients with autoimmune diseases. The company's lead product candidate in development include omilancor, a gut-restricted oral therapeutic candidate that targets lanthionine synthetase C-like protein 2 (LANCL2) for the treatment of ulcerative colitis (UC), Crohn's disease (CD), and
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD